Healthcare

OncoSil Medical continues to progress theManufacturingand commercialisation of its OncoSil brachytherapy technology for locally advanced pancreatic cancer. During 2026, the company advanced manufacturing validation and related commercialisation activities. Its current focus is on strengthening manufacturing capability and establishing a pathway for broader adoption of …

Key catalysts include data readouts from the registrational SAR-bisPSMA studies and any regulatory feedback from the US Food and Drug Administration. Progress onManufacturingandSupplyarrangements for its copper isotopes will also be closely followed, given the logistical demands of radiopharmaceutical distribution. Any partnering, licensing or capital-raising …

Telix develops and commercialises targeted therapeutic and diagnostic radiopharmaceuticals, products that use radioactive isotopes attached to targeting molecules to image and treat disease. Its commercial base is anchored by its prostate-cancer imaging agent, which has driven rapidRevenuegrowth in the key US market.

Cochlear designs, manufactures and supplies implantable hearing solutions and related products and services globally. Its business benefits from both new cochlear implant procedures and the established installed base of recipients, which provides ongoing demand for upgrades, accessories and services. The company continues to invest …

Chimeric Therapeutics is a clinical-stage biotechnology company developing cell therapies for cancer. Its portfolio has included CAR T-cell and natural killer cell programs designed to target solid tumours and blood cancers. The company’s work involves translating laboratory research into clinical protocols, securing manufactured cell …

Ceryvyn Therapeutics, formerly Opthea, is a biopharmaceutical company built around research into the VEGF-C, VEGF-D and VEGFR-3 pathways. Its principal clinical work has centred on sozinibercept, a VEGF-C/D inhibitor studied in combination with therapies that inhibit VEGF-A for wet age-related macular degeneration. The company’s …

Rhythm Biosciences is developing ColoSTAT, a blood-based test intended to support colorectal cancer detection. The test measures a panel of biomarkers and applies an algorithm to generate a result. The company’s activities span assay development, clinical evidence,Manufacturingand the regulatory and commercial work needed to …